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Salivary gland malignancy is rare, with a global annual incidence of 
3 per 100 000 people.[1,2] A rare salivary gland tumour, mammary 
analogue secretory carcinoma (MASC), has only recently been 
described.[3] The few reports and studies concerning MASC have been 
published in several pathology journals. We report a case of a MASC 
of the right parotid salivary gland. Ethics approval was obtained from 
the University of Pretoria Faculty of Health Sciences Research Ethics 
Committee (ref. no. 384/2016).  
Case report
A 28-year-old man presented to Kalafong Hospital, Pretoria, South 
Africa, with a 1-year history of a slow-growing right cheek mass. The 
mass was not painful and there was no history of trauma to the face. 
Clinically, the patient was well, with a non-tender, firm, mobile 4 × 
3 cm parotid tumour. The right facial nerve was intact. The patient 
tested negative for HIV. Fine needle aspiration biopsy showed the 
features to be characteristic of a pleomorphic adenoma. The patient 
underwent a superficial parotidectomy.
Macroscopically, a tan-white homogeneous nodule of 0.8 cm 
was present in the lateral aspect of the parotid gland. Histological 
examination of sections from the superior aspect showed apparently 
normal parotid salivary gland tissue. Examination of the lateral aspect 
showed a relatively circumscribed area with a lobulated architecture 
traversed by thick fibrous septa (Fig. 1). Microcystic growth with 
dilated areas and papillary-cystic growth patterns with papillary 
projections were seen (Fig. 2). Tumour islands punctuated by 
microcysts were scattered within the sclerosed stroma. The papillae 
were lined by bland cells with abundant eosinophilic to vacuolated 
cytoplasm. Some cells had a hobnail appearances and low-grade 
vesicular round-to-ovoid nuclei, with finely granular chromatin 
and conspicuous nucleoli (Fig. 3). The wall appeared markedly 
hyalinised and sclerosed. A chronic lymphocytic inflammatory 
infiltrate was present in the wall. Partial infiltration into the salivary 
gland was seen in areas. No necrosis or mitotic figures were present. 
Inspissated secretions and abundant eosinophilic homogeneous 
secretory material were present. 
Immunohistochemistry showed strong diffuse staining with the 
keratin marker CK7 and patchy positivity with S-100 protein. DOG-1 
and P63 were negative. Intracytoplasmic and intraluminal mucus was 
highlighted with periodic acid-Schiff (PAS) (Fig. 4). The histological 
features were compatible with the rare, recently described MASC. 
There were no projections of the tumour toward the deep lobe of the 
parotid gland. 
The patient underwent adjuvant radiotherapy. At 8 months post 
excision, he was well with no signs of recurrence.
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Mammary analogue secretory carcinoma (MASC) is a rare and recently described tumour of the salivary glands. MASC has similar 
histomorphological and immunohistochemical features of secretory carcinoma of the breast. MASC can be mistaken for other salivary 
gland tumours, especially acinic cell carcinoma. A 28-year-old man was diagnosed with a rare salivary gland tumour in Pretoria, South 
Africa (SA). To our knowledge, a report of MASC in SA has not previously been published. The surgeons dealing with salivary gland 
tumours should be aware of the clinical presentation. Current treatment is similar to that of other salivary gland malignancies. 
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Fig. 1. MASC: multinodular tumour separated by fibrous bands (arrow).
Fig. 2. Area with papillary growth (arrows). 
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Discussion
In 2010, Skálová et al.[3] published a description of 16 cases of salivary 
gland tumours, which were reminiscent of secretory (juvenile) 
carcinoma of the breast, and subsequently proposed MASC to 
describe the tumours.[4] Secretory carcinoma is a rare tumour of the 
breast with a characteristic histological appearance.[5] 
Breast and salivary gland tissues are derived from the same 
ectodermal embryonic origin.[2] Salivary and mammary gland 
tissue have identical ductulo-acinar architecture. Both tumours 
consist of microcystic and solid areas with abundant vacuolated 
colloid-like PAS-positive secretions within the microcystic spaces.[6,7] 
Both tumours are triple (ER/PR/Her-2)-negative. Breast secretory 
carcinomas are clinically slow growing, recur locally, occur mainly 
in young females and generally have a favourable outcome.[4] MASC 
can be clinically slow growing or have an aggressive pattern with 
metastases and increased mortality.[3]
MASC can be mistaken for acinic cell carcinoma; however, MASC 
does not have acinar cells with cytoplasmic PAS-positive, zymogen-like 
granules.[3] The majority of MASC cases were previously diagnosed as 
‘zymogen-poor’ acinic cell carcinoma, but also have similar features 
to low-grade cribiform cystadenocarcinoma, adenocarcinoma not 
otherwise specified, and low-grade muco-epidermoid carcinoma.[9,10]
Acinic cell carcinoma of the breast is composed of cells arranged 
in microcystic, solid and microglandular areas, and resembles acinic 
cell carcinoma of the salivary glands. The immunohistochemical 
and clinicopathological findings of salivary acinic cell carcinoma are 
similar to those of breast secretory carcinomas.[3]
MASC is rubbery and has a white-to-grey surface when cut. 
Microscopically, the tumour is a circumscribed (but not encapsulated) 
multinodular mass divided by fibrous septa with microcystic, 
glandular and solid growth patterns.[4,8] Tumour cells are relatively 
uniform.[11] The tumour can invade within the salivary gland and 
can extend into the surrounding structures.[3,8] The tumour cells 
have low-grade vesicular nuclei, finely granular chromatin and a 
distinctive centrally located nucleolus. The nucleus is surrounded by 
pale eosinophilic granular or vacuolated cytoplasm.[3,4] Mitotic rates 
are usually 0 - 1 mitotic figures/10 high-powered fields.[12]
Immunohistochemical studies show positive staining with vimentin, 
mammaglobin, cytokeratin 7 and S-100 protein.[3,8] Mammaglobin 
and S-100 protein can also be positive in polymorphous low-
grade adenocarcinomas and some adenoid cystic carcinomas.[13] 
Immunohistochemical stains are negative for DOG-1 and p63.[14] 
Skálová et al.[3] showed that MASCs are associated with a recurrent 
chromosomal translocation t(12;15) (p13;q25), which results in 
a fusion gene between the ETV6 gene (chromosome 12) and the 
NTRK3 gene (chromosome 15). This ETV6-NTRK3 gene encodes for 
a chimeric tyrosine kinase.[3,4,7,15] Secretory carcinoma of the breast 
also has a recurrent chromosomal translocation t(12;15) (p13;q25), 
which also occurs some cases of myelogenous leukaemia, infantile 
fibrosarcoma and congenital mesoblastic nephroma.[12] Currently, 
salivary MASC is the only salivary gland tumour to harbour 
the recurrent chromosomal translocation t(12;15) (p13;q25).[4] 
ETV6-NTRK3 gene fusion definitively diagnoses MASC, but not all 
laboratories are equipped to perform this highly specialised test.
The reported cases of MASC are diagnosed in the major 
salivary glands; the majority in the parotid gland. These tumours 
also occur in the minor salivary glands of the oral cavity. MASC 
has been documented in the lip, soft palate, hard palate, base of 
tongue and buccal mucosa.[2,12,16] The reported cases are usually 
in males, with a male:female ratio of 1.5:1.[2,4,17] According to a 
retrospective study from 1990 to 2012 by Min et al.,[8] the average 
age of diagnosis is 46 years, with a usual range of 14 - 77 years.[2,8] 
The youngest reported case occurred in a 5-year-old girl.[18] The 
size of MASC ranges from 1.77 to 2.5 cm.[3,8,10] MASCs in the oral 
cavity are usually smaller (mean 0.9 cm) than those in the major 
salivary glands.[12,19]
MASC is considered to be a low-grade carcinoma that is slow-
growing, painless and with a relatively favourable prognosis.[7,12] It 
does not usually infiltrate surrounding structures, and perineural 
and vascular invasion is unusual.[12] MASCs have a 15% risk of local 
recurrences, especially if incompletely excised.[7] Simple enucleation 
of the tumour has a higher risk of local recurrence compared with 
excision.[7] MASCs have a 20% risk of lymph node metastases and 
5% risk of distant metastases. Local recurrence usually occurs before 
distant metastases or tumour-related death.[7]
High-grade transformation is associated with an accelerated 
clinical course and poor outcome. Skálová et al.[3] reported 
on three patients with high-grade transformed MASC who 
received parotidectomy. Two of the three received postoperative 
radiotherapy, the third patient’s condition being too poor to 
complete radiotherapy. All three died of metastatic disease within 
2 - 6 years of diagnosis.[7]
Clinical stage at diagnosis is the most accurate predictor of 
prognosis. Treatment recommendations are tentative, as there has 
been a limited number of cases of MASC with published follow-up 
data.[20] The role of adjuvant radiotherapy has not been assessed 
in patients with MASC. However, in the presence of high-grade 
transformed MASC, radical surgery with neck dissection followed by 
adjuvant radiotherapy is advised.[7] The optimal follow-up period for 
MASC is also not currently determined.
Fig. 3. Area with microcystic pattern and prominent intraluminal secretions 
(arrow head). Nuclei with finely granular chromatin and conspicuous 
nucleoli (arrows).
Fig. 4. Secretions are highlighted with PAS stain (arrow).
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Some ETV6-NTRK3-positive leukaemias respond to tyrosine 
inhibitors. MASC may therefore also respond favourably by targeting 
the ETV6–NTRK3 translocation, as a potential therapy, especially for 
the high-grade transformation MASC.[12]
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